Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.69 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSL | P07711 | 6/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789616 | 0.86 | ITGB3 (0.71) | ITGB3ITGA2BF10CTSKCTSL | |
| SCHEMBL8542353 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BF10GFERSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8542083 | 0.82 | ITGB3 (0.47) | ITGB3ITGA2BF10GFERSMN1; SMN2 | |
| SCHEMBL7014192 | 0.81 | ITGB3 (1.00) | ITGB3ITGA2BF10 | |
| SCHEMBL8548825 | 0.81 | ITGB3 (0.48) | ITGB3ITGA2BF10GFERSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6786102 | 0.81 | ITGB3 (0.47) | ITGB3ITGA2BF10GFERSMN1; SMN2 | |
| SCHEMBL6792014 | 0.80 | ITGB3 (0.70) | ITGB3ITGA2BTGM2CTSKCTSL | |
| SCHEMBL8548990 | 0.79 | ITGB3 (0.45) | ITGB3ITGA2BF10 | |
| SCHEMBL6793529 | 0.79 | CCR1 (0.44) | ITGB3ITGA2BF10TGM2CTSB | |
| SCHEMBL14305072 | 0.78 | TGM2 (0.54) | ITGB3ITGA2BTGM2CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ITGB3 254/4885ITGA2B 708/4885F10 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.